Prescription Drug User Fee Act
Generated by GPT-5-miniExpansion Funnel Raw 54 → Dedup 0 → NER 0 → Enqueued 0
| Prescription Drug User Fee Act | |
|---|---|
| Name | Prescription Drug User Fee Act |
| Enacted by | United States Congress |
| Enacted | 1992 |
| Signed by | George H. W. Bush |
| Effective | 1992 |
| Related legislation | Federal Food, Drug, and Cosmetic Act |
| Status | active |
Prescription Drug User Fee Act
The Prescription Drug User Fee Act (PDUFA) is a United States statute that authorizes the Food and Drug Administration to collect fees from pharmaceutical companies to fund the review of human drug applications. Enacted in 1992 during the administration of George H. W. Bush, the law links fee revenues to performance goals for application review and has been periodically reauthorized by successive sessions of the United States Congress. PDUFA has shaped interactions among regulators, manufacturers, legislators, and patient advocacy groups such as PhRMA, American Cancer Society, and Susan G. Komen.
Background and Legislative History
PDUFA was developed in response to criticisms of prolonged review times at the Food and Drug Administration and pressure from industry groups like Pharmaceutical Research and Manufacturers of America to accelerate approvals. Key legislative actors included members of the United States Senate and the United States House of Representatives who negotiated provisions with FDA leadership under David Kessler and later commissioners such as Jane Henney and Margaret Hamburg. The 1992 statute built on precedents in regulatory financing observed in statutes affecting agencies such as the Federal Aviation Administration and aligned with advocacy from patient organizations including Leukemia & Lymphoma Society and Alzheimer's Association. Subsequent political milestones—such as debates in the 109th United States Congress, 112th United States Congress, and administrations of Bill Clinton, George W. Bush, Barack Obama, and Donald Trump—shaped reauthorization negotiations.
Provisions and Fee Structure
PDUFA established distinct fee categories: application fees, establishment fees, and product fees tied to specific submission types like new drug applications (NDAs) and biologics license applications (BLAs). Fee schedules have been set in appropriations acts and negotiated with stakeholders from entities including PhRMA, Biotechnology Innovation Organization, and federal budget officials such as those in the Office of Management and Budget. The statute specifies adjustments for inflation and waivers for small businesses, invoking thresholds related to registrants like contract manufacturers and sponsors that appear in filings with the Securities and Exchange Commission. Amendments have created separate fee frameworks for prescription biologics, influenced by rulings and statutes such as the Biologics Price Competition and Innovation Act.
Implementation and Administration
Administration of PDUFA is carried out by the Food and Drug Administration's Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER), with oversight from the Department of Health and Human Services and congressional committees including the Senate Committee on Health, Education, Labor, and Pensions and the House Committee on Energy and Commerce. FDA issues annual guidance and performance reports, and negotiates user fee agreements with industry trade groups like PhRMA and the Biotechnology Innovation Organization. Implementation relies on internal FDA resources and organizational reforms championed by commissioners such as Scott Gottlieb and administrators in the Office of Regulatory Affairs to meet goals in timeliness, staffing, and review capacity.
Impact on Drug Approval Timelines and FDA Performance
Studies and reports by entities including the Government Accountability Office, National Academies of Sciences, Engineering, and Medicine, and academic centers at institutions like Johns Hopkins University and Harvard University attribute reductions in median review times to PDUFA funding and performance targets. Milestones such as increases in approvals for oncology agents, orphan drugs, and biologics have been documented in analyses by FDA staff and industry reports from EvaluatePharma and IQVIA. Critics and supporters alike cite correlations between fee-driven resource increases and metrics such as action dates met under PDUFA goals; these debates have appeared in hearings before the United States Senate Committee on Appropriations and publications in journals associated with New England Journal of Medicine and Health Affairs.
Criticisms and Controversies
Critics from organizations such as Union of Concerned Scientists and academics at Yale University and University of California, San Francisco argue that reliance on industry fees may create perceived conflicts of interest and regulatory capture concerns raised in inquiries by the Government Accountability Office. Controversies include debates over accelerated approval pathways, postmarketing surveillance deficiencies highlighted by cases involving drugs reviewed under expedited programs, and disputes involving pharmaceutical firms including Pfizer, GlaxoSmithKline, and Johnson & Johnson. Congressional hearings in the 110th United States Congress and subsequent sessions examined whether fee incentives shifted priorities away from safety toward speed, with testimony from patient advocates like Patients for Affordable Drugs Now and researchers from Boston University.
Reauthorizations and Amendments
PDUFA has been reauthorized approximately every five years, resulting in successive user fee agreements that adjust fee levels, performance goals, and program scope. Major reauthorizations occurred through legislation influenced by Senators and Representatives including leaders from the Senate Committee on Health, Education, Labor, and Pensions and the House Committee on Energy and Commerce, producing PDUFA II, III, IV, V and later iterations that refined provisions for user fee sunset dates, performance enhancements, and commitments to safety programs. Amendments have intersected with statutes like the Food and Drug Administration Safety and Innovation Act and provisions tied to biologics, pediatric exclusivity, and postmarketing requirements advocated by stakeholders including American Society of Clinical Oncology and National Organization for Rare Disorders.